Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose.
  • Published Date:

    March 5, 2004

  • Source:
    MMWR. Morbidity and mortality weekly report. 2004; 53(8):177-8.
  • Language:
Filetype[PDF-449.72 KB]

  • Alternative Title:
    MMWR. Morbidity and mortality weekly report
  • Description:
    On February 13, 2004, CDC recommended that health-care providers temporarily suspend routine use of the fourth dose of 7-valent pneumococcal conjugate vaccine (PCV7) when vaccinating healthy children. This action was taken to conserve vaccine and minimize the likelihood of shortages until Wyeth Vaccines, the only U.S. supplier of PCV7 (marketed as Prevnar), restores sufficient production capacity to meet the national need. Since that recommendation, PCV7 production has been much less than expected because of continuing problems with the PCV7 vial-filling production line. Shipments have been delayed, resulting in spot shortages that might continue beyond summer 2004 and become widespread. Effective immediately, to further conserve vaccine, CDC recommends that all health-care providers temporarily suspend routine administration of both the third and fourth doses to healthy children.
  • Pubmed ID:
  • Document Type:
  • Main Document Checksum:
  • File Type:
  • Supporting Files:
    No Additional Files
No Related Documents.

You May Also Like: